Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

Ann Oncol · 2013 · PMC3718507 · PMID 23670096

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

reached borderline significanceP = 0.064so close (0.05 < p ≤ 0.1)

A test for interaction between AIB1 and tamoxifen benefit reached borderline significance ( P = 0.064).

also in 370 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.